Rivaroxaban

Pancreas Cancer

Hôpital FribourgeoisSmall moleculeN/AActive

D

30/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 15/ 100
Competitive Position: 73/ 100

Competitive context

81 Active assets in the Pancreas Cancer cohort.

Asset / Sponsor	Phase	Rating
Epirubicin TME Pharma AG	Phase 3	BB
Pembrolizumab Essen Biotech	Phase 2	BB
Surufatinib Tianjin Medical University Cancer Institute and Hospital	Phase 3	BB
Docetaxel Minia University	Phase 3	BB
PANITUMUMAB SWOG Cancer Research Network	Phase 3	BB

View all 50 →

Same molecule, other indications

Rivaroxaban is also rated in:

atrial fibrillationDormant

BBB

Indicative ·

79 / 100

hemorrhagic diseaseDormant

BBB

Indicative ·

76 / 100

thrombotic diseaseDormant

BBB

Indicative ·

76 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.